EUCTR2007-007258-75-SE进行中（未招募）不适用
A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Disease related:
- •Diagnosis of MDS using the WHO classification
- •Per MDS IPSS, Low or intermediate-1 risk MDS
- •The mean of the two platelet counts taken within 4 weeks prior to randomization must be:
- •- = 20 x 109/L, with no individual count >30 x 109/L with or without a history of bleeding, OR
- •- = 50 x 109/L, with no individual count > 60 x 109/L with a history of bleeding .
- •A standard of care platelet count taken prior to Informed Consent may be used as 1 of the 2 counts taken within 4 weeks prior to randomization.
- •Demographic:
- •Subjects must be =18 and = 90 years of age at the time of informed consent. Subjects between 85 and 90 years of age must have been diagnosed with MDS = 5 years from study start.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- •Laboratory:
- •Adequate liver function, as evidenced by a serum bilirubin = 2 times the laboratory normal range and unconjugated bilirubin = 90% of total bilirubin (except for patients with a confirmed diagnosis of Gilbert’s Disease), ALT = 3 times the laboratory normal range, and AST = 3 times the laboratory normal range.
- •A serum creatinine concentration = 2 mg/dl (=176.8 µmol/L)
- •Bone marrow biopsy and aspirate with cytogenetics within 3 months of the first dose of investigational product.
- •Before any study-specific procedure, the appropriate written informed consent must be obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Disease Related:
- •Have ever received any disease-modifying treatment for MDS
- •Previously diagnosed with intermediate-2 or high risk MDS with IPSS
- •Prior history of leukemia, aplastic anemia, or other non-MDS related bone marrow stem cell disorder
- •Prior history of hematopoietic stem cell transplantation
- •Persistent peripheral blood monocytosis (= 3 months with an absolute monocyte count >1,000/µL)
- •Prior malignancy (other than in situ cervical cancer, non-melanoma skin cancer, or in situ carcinoma) unless treated with curative intent and without evidence of disease for =3 years before randomization
- •Active or uncontrolled infections
- •Unstable angina, congestive heart failure (NYHA > class II), uncontrolled hypertension (diastolic > 100 mmHg), uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction
- •History of arterial thrombosis (eg, stroke or transient ischemic attack) in the past year
- •History of venous thrombosis that currently requires anti-coagulation therapy
- •Laboratory:
- •Pregnant or breast feeding
- •Medications
- •Received IL-11 within 4 weeks of screening
- •Have previously received any thrombopoietic growth factor
- •Receipt of G-CSF, peg-G-CSF, or GM-CSF within 4 weeks of the first dose of investigational product.
- •Planned receipt of peg-G-CSF or GM-CSF after the first dose of investigational product.
- •Subject of reproductive potential who is not using adequate contraceptive precautions, in the judgement of the investigator. Amgen recommends double barrier contraception is used for all applicable patients enrolled on this study. A double barrier method is defined as two methods of contraception, for example 2 actual barrier methods, or one actual barrier method and one hormonal method.
- •Subject has known sensitivity to any E coli-derived product (eg, Infergen®, Neupogen®, Somatropin, and Actimmune®).
- •Subject previously has entered this study.
- •Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.
- •Subject currently is enrolled in or has not yet completed 30 days since ending other investigational device or drug study.
研究者
相似试验
进行中（未招募）
不适用
A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)EUCTR2007-007258-75-ATAmgen Inc240
进行中（未招募）
不适用
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)EUCTR2007-007258-75-NLAmgen Inc240
进行中（未招募）
1 期
A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)EUCTR2007-007258-75-FRAmgen Inc240
进行中（未招募）
1 期
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)ow or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)MedDRA version: 16.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-007258-75-DEAmgen Inc250
进行中（未招募）
不适用
A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)ow or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)MedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2007-007258-75-HUAmgen Inc240